Literature DB >> 23916692

Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer.

Frédéric D Birkhäuser1, Urs E Studer, Johannes M Froehlich, Maria Triantafyllou, Lauren J Bains, Giuseppe Petralia, Peter Vermathen, Achim Fleischmann, Harriet C Thoeny.   

Abstract

BACKGROUND: Conventional cross-sectional imaging with computed tomography and magnetic resonance imaging (MRI) has limited accuracy for lymph node (LN) staging in bladder and prostate cancer patients.
OBJECTIVE: To prospectively assess the diagnostic accuracy of combined ultrasmall superparamagnetic particles of iron oxide (USPIO) MRI and diffusion-weighted (DW) MRI in staging of normal-sized pelvic LNs in bladder and/or prostate cancer patients. DESIGN, SETTING, AND PARTICIPANTS: Examinations with 3-Tesla MRI 24-36 h after administration of USPIO using conventional MRI sequences combined with DW-MRI (USPIO-DW-MRI) were performed in 75 patients with clinically localised bladder and/or prostate cancer staged previously as N0 by conventional cross-sectional imaging. Combined USPIO-DW-MRI findings were analysed by three independent readers and correlated with histopathologic LN findings after extended pelvic LN dissection (PLND) and resection of primary tumours. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Sensitivity and specificity for LN status of combined USPIO-DW-MRI versus histopathologic findings were evaluated per patient (primary end point) and per pelvic side (secondary end point). Time required for combined USPIO-DW-MRI reading was assessed. RESULTS AND LIMITATIONS: At histopathologic analysis, 2993 LNs (median: 39 LNs; range: 17-68 LNs per patient) with 54 LN metastases (1.8%) were found in 20 of 75 (27%) patients. Per-patient sensitivity and specificity for detection of LN metastases by the three readers ranged from 65% to 75% and 93% to 96%, respectively; sensitivity and specificity per pelvic side ranged from 58% to 67% and 94% to 97%, respectively. Median reading time for the combined USPIO-DW-MRI images was 9 min (range: 3-26 min). A potential limitation is the absence of a node-to-node correlation of combined USPIO-DW-MRI and histopathologic analysis.
CONCLUSIONS: Combined USPIO-DW-MRI improves detection of metastases in normal-sized pelvic LNs of bladder and/or prostate cancer patients in a short reading time.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Diffusion-weighted MRI; Lymph node metastasis; Pelvic lymph node dissection; Prostate cancer; USPIO

Mesh:

Substances:

Year:  2013        PMID: 23916692     DOI: 10.1016/j.eururo.2013.07.032

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  52 in total

Review 1.  Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2015-10-19       Impact factor: 4.104

Review 2.  Preoperative imaging for staging bladder cancer.

Authors:  Maxim J McKibben; Michael E Woods
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

3.  Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study.

Authors:  Baris Turkbey; Marcin Czarniecki; Joanna H Shih; Stephanie A Harmon; Piyush K Agarwal; Andrea B Apolo; Deborah E Citrin; James L Gulley; Mukesh Harisinghani; Ravi A Madan; Adam R Metwalli; Edmond Paquette; Peter A Pinto; Soroush Rais-Bahrami; Lindsay S Rowe; Bradford J Wood; Paula M Jacobs; Liza Lindenberg; William Dahut; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2019-10-15       Impact factor: 3.959

Review 4.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 5.  Diffusion weighted magnetic resonance imaging and its recent trend-a survey.

Authors:  Geetha Soujanya Chilla; Cher Heng Tan; Chenjie Xu; Chueh Loo Poh
Journal:  Quant Imaging Med Surg       Date:  2015-06

6.  Prostate cancer: Can imaging accurately diagnose lymph node involvement?

Authors:  Jelle O Barentsz; Harriet C Thoeny
Journal:  Nat Rev Urol       Date:  2015-05-05       Impact factor: 14.432

7.  A Phase I Dosing Study of Ferumoxytol for MR Lymphography at 3 T in Patients With Prostate Cancer.

Authors:  Baris Turkbey; Harsh K Agarwal; Joanna Shih; Marcelino Bernardo; Yolanda L McKinney; Dagane Daar; Gary L Griffiths; Sandeep Sankineni; Linda Johnson; Kinzya B Grant; Juanita Weaver; Soroush Rais-Bahrami; Mukesh Harisinghani; Paula Jacobs; William Dahut; Maria J Merino; Peter A Pinto; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2015-07       Impact factor: 3.959

Review 8.  Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

Authors:  Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

9.  Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.

Authors:  J W Yaxley; J Dagher; B Delahunt; L Egevad; J Srigley; H Samaratunga
Journal:  World J Urol       Date:  2017-11-07       Impact factor: 4.226

Review 10.  Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery.

Authors:  Marie Stark; R Holland Cheng
Journal:  Pharm Pat Anal       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.